• The future of cancer care

    Funding research to identify therapies for diseases that have no cure, such as rare genetic diseases and hard-to-treat cancers.

  • What we do

    broken image

    New Techniques

    The future of cancer care

    Although medicine has made lots of progress in treating many cancers, much progress still needs to be made. Amongst the hardest cancers to treat, and those with the poorest outcomes, are gastrointestinal and rare cancers. Fortunately, new techniques mean that treatment for these cancers can be personalised, dramatically improving survival rates.

    broken image

    Funding Assistance

    The challenge of access

    Imagine being diagnosed with one of these harder-to-treat cancers, being told that new treatments were now available that are much more successful, but then realising that you cannot afford the innovative new treatment. This is the problem that My Personal Therapeutics Foundation exists to address. If you think you could benefit from funding assistance then please contact us through our confidential form.

  • broken image

    How we help patients

    My Personal Therapeutics Foundation provides financial aid to patients with gastrointestinal and rare cancers, so that they can access the very latest in personalised treatments. We support anyone, in any country, provided you can be helped by our therapeutic partner, and meet our financial aid criteria. If you think that you meet our criteria then please contact us through our confidential form:

  •  

    My Personal Therapeutics Foundation is fortunate to be able to work with one of the leading personalised cancer companies - Vivan Therapeutics.

     

    The Icahn School of Medicine at Mount Sinai developed the Personal Discovery Process (PDP) methodology over years of clinical research. PDP identifies the precise combination of FDA-approved drugs (including non-cancer drugs) that works optimally on your patient’s specific tumour, mirroring its genetic complexity and increasing the prospects of an efficient treatment while also reducing toxicity and side effects.

     

    Our preferred partner VivanTx is a leading biotech company, based in London, who offer advanced personalised cancer therapeutics to patients worldwide in partnership with patients own oncologists.

     

  • Donate Now

    Donate to make and make a REAL difference.

     

    Find a Lifeline for Nora

    Find a Lifeline for Nora

    $10.00 - $5,000.00
    At just 7, Nora's vibrant spirit shines despite her battle with the devastating ECHS1 Deficiency, Leigh-like Syndrome. Her adorable joy is inspiring yet makes her parent's search for therapies more urgent. Already Noa has her vision impaired, is tube-fed, and is unable to walk or talk. Yet, their warrior princess finds so much joy in music, cartoons, and her loving family, including Lulu, her loyal pup. The heartache of losing Anna, her sister, further drives the search for a custom therapy that will give Nora, and others like her, the chance to more fully embrace life.
    View more details...
    Select
    Quantity
    Coming soon
    Cover A Patient's Personalised Drug Combination

    Cover A Patient's Personalised Drug Combination

    $13,768.00
    Cover the costs of the full genetic and AI drug combination discovery process including backup combination discovery.
    Quantity
    Coming soon
    Be Part of a Patient Journey

    Be Part of a Patient Journey

    $100.00 - $2,000.00
    Be part of funding a patient through the initial sequencing.
    Select
    Quantity
    Coming soon
  • About MPTF

    The MPT Foundation was founded in 2019, to assist patients needing financial assistance in accessing cutting-edge personalised cancer therapeutics specifically from VivanTx.

    broken image

    BILL LIAO

    MD

    Mr Liao is a Trustee of several global charities such as the SENS foundation and Social Tech Trust. He is also a general partner with SOSV and Co-Founder of their IndieBio program.

    broken image

    LAURA TOWART

    CEO

    Laura formed the My Personal Therapeutics Foundation to raise funds to support the identification of new therapeutic options for patients who need them. The MPTF supports patients who could benefit from personalised treatment but who otherwise wouldn't be able to afford such therapies.

    broken image

    OLIVER SMITH

    STRATEGY ADVISOR

    Oliver is a strategy adviser and applied ethicist. He was Strategy Director and Head of Ethics at Koa Health from 2016 to 2022. He was also a Senior Civil Servant in the UK Department of Health and a Policy Adviser in the Prime Minister’s Strategy Unit under Tony Blair.

    broken image

    STEVE LEWIS

    LEAD DESIGNER

    With 15 years of practice in helping people understand the wavy—and often blurry—line between user behavior and user experience, Steve has led the way in creating beautiful, aesthetic UIs driven by human-centric discovery and insight across several industries.

  • Contact Us

    Feel free to contact us to learn more

    The WestWorks, Part First Floor, Unit 5, 195 Wood Lane, London W12 7FQ